Atea Pharmaceuticals (NASDAQ:AVIR – Get Free Report) is expected to be issuing its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.
Atea Pharmaceuticals Trading Down 1.0 %
Shares of NASDAQ:AVIR opened at $3.03 on Friday. The firm has a market capitalization of $255.92 million, a PE ratio of -1.46 and a beta of 0.19. Atea Pharmaceuticals has a 1-year low of $2.75 and a 1-year high of $4.60. The business’s 50 day moving average is $3.19 and its 200-day moving average is $3.37.
Insider Buying and Selling
In related news, Director Franklin M. Berger sold 359,606 shares of the firm’s stock in a transaction that occurred on Tuesday, December 10th. The stock was sold at an average price of $2.85, for a total transaction of $1,024,877.10. Following the completion of the transaction, the director now owns 451,897 shares in the company, valued at $1,287,906.45. This trade represents a 44.31 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 17.80% of the stock is owned by corporate insiders.
About Atea Pharmaceuticals
Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.
Read More
- Five stocks we like better than Atea Pharmaceuticals
- What is a buyback in stocks? A comprehensive guide for investors
- Analysts Lift Archer Aviation Stock Despite Earnings Miss
- Canadian Penny Stocks: Can They Make You Rich?
- 5 Best Gold ETFs for March to Curb Recession Fears
- What Is WallStreetBets and What Stocks Are They Targeting?
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
Receive News & Ratings for Atea Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atea Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.